Get the Stockscreener App
29.48
1.64%
-0.493
Second Sight Medical Products, stock is traded at $29.48, with a volume of 800.
It is down -1.64% in the last 24 hours and up +2.48% over the past month.
Second Sight Medical Products, Inc., together with its subsidiaries, develops, manufactures, and markets prosthetic devices to restore functional vision of blind individuals in the United States, Canada, Europe, the Middle East, and Asia. It offers Argus II System, which treats outer retinal degenerations, such as retinitis pigmentosa. The company was formerly known as Second Sight LLC. and changed its name to Second Sight Medical Products, Inc. Second Sight Medical Products, Inc. was founded in 1998 and is headquartered in Sylmar, California.
See More
Previous Close:
$29.97
Open:
$29.71
24h Volume:
800
Relative Volume:
1.23
Market Cap:
$N/A
Revenue:
$3.38M
Net Income/Loss:
$-8.29M
P/E Ratio:
-134.00
EPS:
-0.22
Net Cash Flow:
$-1.99M
1W Performance:
+0.86%
1M Performance:
+2.48%
6M Performance:
+1,575%
1Y Performance:
+1,575%
1-Day Range:
$29.48
$29.71
1-Week Range:
$29.34
$30.28
52-Week Range:
$1.58
$30.39
Second Sight Medical Products, Stock (EYES) Company Profile
Name
Second Sight Medical Products,
Sector
Industry
Phone
818-833-5000
Address
12744 San Fernando Road, Suite 400, Sylmar
Compare EYES vs VOO, IVV, SPY, VTI, QQQ
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EYES
Second Sight Medical Products,
|
29.48 | 0 | 3.38M | -8.29M | -1.99M | -0.22 |
VOO
Vanguard S P 500 Etf
|
706.83 | 1.04T | 0 | 0 | 0 | 0.00 |
IVV
Ishares Core S P 500 Etf
|
772.36 | 886.29B | 0 | 0 | 0 | 0.00 |
SPY
Spdr S P 500 Etf Trust
|
768.96 | 812.12B | 0 | 0 | 0 | 0.00 |
VTI
Vanguard Total Stock Market Etf
|
376.65 | 693.71B | 0 | 0 | 0 | 0.00 |
QQQ
Invesco Qqq Trust Series 1
|
729.95 | 488.19B | 0 | 0 | 0 | 0.00 |
Second Sight Medical Products, Stock (EYES) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-19 | Initiated | Dougherty & Company | Buy |
| Jul-06-15 | Initiated | H.C. Wainwright | Buy |
Second Sight Medical Products, Stock (EYES) Latest News
Palantir's Growth Story Gets a Goldman Boost: ETFs to Consider - The Globe and Mail
Palantir's Growth Story Gets a Goldman Boost: ETFs to Consider - Zacks Investment Research
Best Performing ETFs: Top Returns at a Glance - TradingKey
Second Sight Medical Products Inc (VANIW) Key Financial Ratios – Valuation, Profitability & More - Value Research
Second Sight Medical Products Inc (VANIW) Peer Comparison – Compare with Others - Value Research
Second Sight Medical Products Inc. Warrants (EYESW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Second Sight Medical Products Inc. Warrants (EYESW) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
Second Sight Medical Products Inc. Warrants (EYESW) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
Second Sight Medical Products Inc. (EYES) Peer Comparison – Compare with Others - Value Research
Second Sight Medical Products Inc (VANIW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Second Sight Medical Products Inc (VANIW) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
ETF Edge on thematic and active ETFs outside of AI and trends to watch - CNBC
Palantir's post-earnings rally puts PLTR-heavy ETFs in focus (PLTR:NASDAQ) - Seeking Alpha
The corgi-inspired ETF provider that wants to disrupt BlackRock - Financial Times
EU Clears PRIMA Retinal Chip for Commercial Sale After AMD Patient Reads 300-Page Novel - The Eastern Herald
Presenting on Emerging Growth Conference 94 Day 1 on July 15; Register to live stream - GlobeNewswire Inc.
ClearOne skyrockets from neurotech pivot, merger with Cortigent - Mugglehead Investment Magazine
Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management - markets.businessinsider.com
Vivani Medical allows Novo Nordisk to evaluate NPM-139 - scanx.trade
ClearOne Merging With Cortigent - Pulse 2.0
Vivani to sell neurotech subsidiary Cortigent to ClearOne - MassDevice
ClearOne Announces Entry into Merger Agreement with Cortigent, Inc., a Wholly-Owned Subsidiary of Vivani Medical - Business Wire
Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker - GlobeNewswire
Vivani Medical appoints August Moretti to board as Dr. Dean Baker retires - scanx.trade
Looking for Exposure to Palantir Stock (PLTR) at New Lows? These 2 ETFs Offer Over 35% Upside - TipRanks
Vivani Medical CEO Adam Mendelsohn to Present at the 2026 BIO International Convention - markets.businessinsider.com
European Union Retinal Implant Electrode ArraysMarket Analysis, Forecast, Size, Trends and Insights - IndexBox
Corgi Quantum Computing ETF (CQTM) stock price, news, quote and history - Yahoo Finance Australia
World Auditory Brainstem ImplantsMarket Analysis, Forecast, Size, Trends and Insights - IndexBox
Visual Prosthesis Market Size, Share, Growth, Forecast, 2034 - Straits Research
Vivani Medical CEO Adam Mendelsohn to Present at the Jefferies Global Healthcare Conference on June 4, 2026 - markets.businessinsider.com
Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update - markets.businessinsider.com
Corgi Data & Surveillance ETF (EYES) Holdings - Yahoo! Finance Canada
EYES ETF Price and Chart — CBOE:EYES - TradingView
Corgi Funds Launches Record 34 ETFs - ETF Database
Corgi Funds Launches Record 34 ETFs - ETF Trends
Corgi Launches 34 ETFs & Raises $160M in a Single Day - ETF.com
/C O R R E C T I O N -- Corgi Funds/ - PR Newswire
EYES ETF Profile: Dividends, Returns (CBOE:EYES) - tradingview.com
Medical Bionic Implant and Artificial Organs Price in the European UnionMarket Insights - IndexBox
Stock List: Research Stocks from Around the World - GuruFocus
Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewswire
Single semaglutide implant showed >20% weight loss for a year - Stock Titan
Stock List: Research Stocks from Around the World - GuruFocus
Promising Six-Year Early Feasibility Study Results Released for the Orion System - Medical Product Outsourcing
Electroceuticals Market Size, Share & Growth Report, 2034 - Market Data Forecast
'Bionic Eye' Helps Man See After Decade of Impaired VisionABC News - ABC News - Breaking News, Latest News and Videos
Don’t Let Elon Musk Implant a Device in Your Skull - Home ❧ Current Affairs
Second Sight Medical Products, Stock (EYES) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):